Company news

Axsome Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

May 26, 2025

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

May 12, 2025

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

April 30, 2025

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

April 7, 2025

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

April 3, 2025

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

March 31, 2025

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

March 24, 2025

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

March 5, 2025

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

March 2, 2025

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

February 23, 2025

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 17, 2025

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

February 9, 2025

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

January 30, 2025

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

January 29, 2025

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

January 12, 2025

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

December 29, 2024

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

November 7, 2024

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

October 28, 2024

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

October 14, 2024

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

September 3, 2024

Axsome Therapeutics to Participate in Investor Conferences in September

August 26, 2024

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

August 20, 2024

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 4, 2024

Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

July 10, 2024

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

June 4, 2024

Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

June 3, 2024

Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

June 2, 2024

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

May 28, 2024

Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting

May 27, 2024

Axsome Therapeutics to Present at Upcoming Investor Conferences

May 7, 2024

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 5, 2024

Axsome Therapeutics Recognizes May as Mental Health Awareness Month

April 30, 2024

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

April 14, 2024

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

April 9, 2024

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

March 31, 2024

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

March 24, 2024

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

March 24, 2024

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

March 18, 2024

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

March 4, 2024

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

February 26, 2024

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 19, 2024

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20

January 22, 2024

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

January 3, 2024

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

December 10, 2023

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

December 6, 2023

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

November 21, 2023

Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 5, 2023

Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023

November 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 48 decks. Every deck is listed under its year.